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ABSTRACT 
 
Introduction 
Based on recent results of several phase II studies with tyrosine kinase inhibitors and 
the better knowledge of molecular aberrations that characterize thyroid carcinogenesis 
a retrospective analysis of patients with metastatic thyroid cancer treated with sorafenib 
was designed. 
Patients and Methods 
The primary end point was objective response rate. Secondary end points included 
toxicity, median progression-free (mPFS) and overall survival, and correlation between 
tumor marker levels (thyroglobulin, calcitonin and CEA) and efficacy. Patients received 
sorafenib 400 mg bid. Response was evaluated every 8-12 weeks using RECISTv1.0 
(Response Evaluation Criteria in Solid Tumors).  
Results 
Thirty-four patients were included in the study between June 2006 and January 2010. 
16 were differentiated thyroid carcinomas (DTC) (7 (23%) were papillary, 9 (26%) 
follicular), 15 (44%) medullary (MTC) and 3 (7%) were anaplastic (ATC). All patients 
were included in the intention-to-treat analysis. 11 patients (32%) reached partial 
response and 14 (41%) had stable disease beyond 6 months. Regarding histological 
subtype, response rates observed were 47% for medullary (7 of 15), 19% for 
differentiated (3 of 16) and 33% (1 of 3) for anaplastic. With a median follow-up of 11.5 
months, mPFS were 13.5, 10.5 and 4.4 months for DTC, MTC and ATC, respectively. 
Tumor markers were evaluated in 22 patients and a statistically significant correlation 
was observed between response rate and decrease in tumor marker levels greater 
than 50% (p=0.033).  
Conclusion 
Sorafenib has showed anti-tumor efficacy in all histological subtypes of thyroid cancer 
in a population-based study and warrants further development in this setting. 
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RESUM 
 
Introducció 
Basat en els resultats recents de diversos estudis fase II amb inhibidors tirosina 
quinasa i del millor coneixement de les alteracions moleculars que caracteritzen el 
procés de carcinogènesi del càncer de tiroides, es va dissenyar un estudi retrospectiu 
de pacients afectes de carcinoma de tiroides metastàtic tractats amb sorafenib. 
Pacients i Mètodes 
L’objectiu primari de l’estudi era la taxa de respostes objectives. Els objectius 
secundaris incloïen toxicitat, mitjana de supervivència lliure de progressió (mSLP), 
supervivència global (mSG) i correlació entre els nivells de marcador tumoral 
(tiroglobulina, calcitonina i CEA) i eficàcia. Els pacients eren tractats amb sorafenib 
400 mg dos cops al dia. La resposta s’avaluava cada 8-12 setmanes utilitzant els 
criteris RECIST v1.0 
Resultats 
Entre juny de 2006 i gener de 2010 trenta quatre pacients es van incloure en l’estudi. 
16 eren carcinomes diferenciats de tiroides (CDT) (7 (23%) eren papil·lars, 9 (26%) 
fol·liculars), 15 (44%) medul·lars (CMT) i 3 (7%) eren anaplàsics (CAT). Tots els 
pacients van ser inclosos en l’anàlisi per intenció de tractar. 11 pacients (32%) van 
aconseguir una resposta parcial i 14 (41%) tenien malaltia estable més enllà dels 6 
mesos. En funció del subtipus histològic, la taxa de respostes observada va ser del 
47% per CMT (7 de 15), 19% per CDT (3 de 16) i 33% (1 de 3) per CAT. Amb una 
mitjana de seguiment de 11.5 mesos, la mSLP va ser de 13.5, 10.5 i 4.4 mesos per 
CDT, CMT i CAT, respectivament. Els marcadors tumorals es van avaluar en 22 
pacients i es va observar una correlació estadísticament significativa entre la taxa de 
respostes i la reducció superior al 50% en els nivells dels marcadors tumorals 
(p=0.033). 
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Conclusió 
Sorafenib ha demostrat una eficàcia antitumoral en tots els subtipus histològics de 
càncer de tiroides en un estudi poblacional i assegura un major desenvolupament en 
aquesta població.   
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INTRODUCTION 
In the last decades the incidence of thyroid gland carcinoma has significantly raised 
becoming the most frequent tumor of the endocrine system1. The estimated number of 
new cases of thyroid cancer in the US for 2010 is 44.670 new cases with 1.690 
estimated deaths2. Differentiated thyroid cancer (DTC) is by far the most common 
tumor type reaching 90% of cases and includes papillary and follicular carcinomas. 
Thyroid gland could develop other important tumor types such as medullary thyroid 
carcinoma (MTC) and anaplastic thyroid cancer far rarer than DTC3.  
The main therapeutic approaches for DTC are the surgical resection and radioactive 
iodine (131I) ablation. These approaches reach a 10-year survival higher than 90% and 
achieve a complete remission of 60% of patients with local recurrence and 30% of 
patients with distant metastases4. So, the overall prognosis of thyroid cancer is 
excellent. However, overall survival dramatically falls when standard therapy fails and 
the 5-years survival rate decreases to less than 50% when radioactive iodine therapy 
loses its activity against DTC5. 
The traditional DNA damaging cytotoxic agents are of limited efficacy in the treatment 
of DTC. The activity of several agents has been evaluated for the treatment of patients 
with DTC with disappointing results. The best studies have shown response rates 
between 0-20%, of short duration, without complete remissions and no impact in 
overall survival. The most developed drug has been doxorubicin alone and in 
combination with other cytotoxics, mainly cisplatin, with no increasing in response rates 
but higher adverse events6, 7. 
Several translational and clinical studies have been designed based on the deeper 
knowledge of the main molecular steps that lead to the transformation of the normal 
follicular cell into an invasive thyroid carcinoma and have opened a more optimistic 
point of view for the treatment of these patients. Thyroid carcinogenesis has become 
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one of the most fascinating models and a particularly promising paradigm for targeted 
therapy.  
A multistep model has been suggested involving the main genetic aberrations that 
carry out the tumor-initiating process from a follicular cell origin and also the so-called 
oncogenic addiction to these particular mutations that make them particularly 
interesting for directed therapy8. One of the most important activating genetic mutations 
involves the RET/PTC-RAS-RAF-MAPK axis. For hereditary medullary thyroid cancer 
(MTC) formation mutations in RET gene are essential in more than 95% of cases and 
also important are for the development of sporadic MTC (50% of cases)9. Activating 
mutations in protein kinase B-type RAF kinase (BRAF) up to 45% of cases play a key 
role in the carcinogenesis of papillary thyroid cancer (PTC), but also RAS mutations 
(10%) and rearrangements in RET gene (RET/PTC) between 5-30% of cases. These 
mutations have also been described in follicular thyroid carcinomas (FTC) affecting in 
more than 40% of cases the three RAS proto-oncogen family (HRAS, NRAS and 
KRAS) and also the genomic rearrangement in up to 50% of FTC involving a 
translocation event between chromosome regions 3p25 and 2q13 resulting in a fusion 
protein (paired box gene 8 (PAX8) with the peroxisome proliferator-activated receptor γ 
(PPARγ) gene). Genetic alterations in RAS-BRAF pathway have also been identified in 
poorly differentiated and anaplastic thyroid carcinomas that arise from PTC with 
accumulation of other important protein mutations that such as p53, β-catenin, or  
phosphatidylinositol-3-kinase (PI3K) mutations. Additionally, upregulation of vascular 
endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGFR) 
expression has been well-described in thyroid cancer and correlated with tumor stage, 
size and lymphatic and distant tumor spread with a detrimental impact in survival10. 
Sorafenib (BAY 43-9006) is the first compound capable to inhibit all the RAF kinases 
that has reached the clinical practice. Moreover, sorafenib targets a panel of tyrosine 
kinase receptors such as VEGF receptors 1-3, PDGFR-β and RET that gives to 
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sorafenib not only proapoptotic properties, but also antiangiogenic effects which are of 
special interest in thyroid carcinomas11. 
A retrospective population-based study evaluating the activity of sorafenib in patients 
with metastatic thyroid cancer has been designed including consecutive patients of 7 
referral centers of Spain: Vall d'Hebron University Hospital, Barcelona; 12 de Octubre 
University Hospital, Madrid; Clinic Hospital, Barcelona; La Fe University Hospital, 
Valencia; Miguel Servet Hospital, Zaragoza; Ramón y Cajal University Hospital, 
Madrid; and Virgen del Rocío University Hospital, Sevilla. 
 
PATIENTS AND METHODS 
Patients 
Eligible patients were ≥ 18 years old with histologically confirmed thyroid carcinoma 
(papillary, follicular or anaplastic subtypes) for which no curative or standard palliative 
therapies were available. Patients had evidence of disease progression by Response 
Evaluation Criteria in Solid Tumors (RECIST) in the 12 months prior to enter into the 
study and all patients had measurable disease by RECIST criteria. Previous therapies 
with radioiodine therapy, radiotherapy, chemotherapy or biologic treatment were 
allowed. Other inclusion criteria included Eastern Cooperative Oncology Group 
performance status ≤ 2, preserved renal, hepatic and bone marrow function. All 
patients provided written informed consent of the Spanish compassionate use program 
as well as hospitals’ pharmacy and direction, and central government authorizations for 
off-label use were obtained for each patient included in this study12.  
Study design 
The study was based on the evaluation of a Spanish off-label program of sorafenib in 
patients with metastatic thyroid carcinoma, including papillary, follicular, medullary and 
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anaplastic subtypes, performed in accordance with the local legislation in 7 Spanish 
referral centers. Sorafenib was administered at a dose of 400 mg twice a day as long 
as it provided clinical benefit or until unacceptable toxicity. A cycle was defined as 4 
weeks and tumor evaluation was performed by CT scan or MRI every 8-12 weeks. 
Tumor marker evaluation, carcinoembrionary antigen (CEA), thyroglobulin and 
calcitonin, was performed every 8-12 weeks. Dose adjustments were made as per 
toxicity profile. 
Study end points and Statistical analysis 
The primary end point was efficacy assessment evaluated in terms of response rate 
(RR), median progression free survival (mPFS) and median overall survival (mOS) 
according to RECIST v 1.0 criteria13. Secondary end points included the toxicity profile, 
evaluated by means of the Common Terminology Criteria for Adverse Events, version 
3.0. (CTC.AE v.3.0) and the correlation between efficacy and tumour marker levels: 
thyroglobulin for differentiated thyroid cancer (DTC) that included PTC and FTC, and 
calcitonin and CEA for MTC.  
Statistical analyses of survival were performed using a one-sided log-rank of Kaplan-
Meier survival estimates and Chi-square distribution for the correlation between tumor 
markers and efficacy. 
 
RESULTS 
Between June 2006 and January 2010, 34 patients were included onto study. Table 1 
summarizes baseline characteristics of the patients entered onto study. Of the 34 
patients with confirmed thyroid cancer, 7 (23%) were papillary, 9 (26%) follicular, 15 
(44%) medullary and 3 (7%) were anaplastic. At baseline, 33 patients (97%) had 
undergone previous surgery, 19 (56%) had received radiotherapy, 13 (38%), 
radioactive iodine therapy, 32% (n=11) chemotherapy and 20% (n=7) somatostatin 
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analogues. All patients presented documented disease progression by RECIST criteria 
previous the inclusion in the trial. 
Efficacy 
A total of 32 patients were evaluable for radiological response, but all 34 patients were 
included in the intention-to-treat analysis. Eleven patients reached partial response 
(PR) and 14 stable disease (SD) beyond 6 month. The disease control rate (PR+SD) 
was 73%. The PR rate by histological subtype was 7/15 (47%) for patients with MTC, 
3/16 (19%) for patients with DTC and 1/3 (33%) for patients with anaplastic 
carcinomas. Disease control rate for MTC patients was 87% and for DTC patients was 
69% (Table 2). Image 1 shows an example of PR in a patient with advanced MTC. 
With a median follow-up of 11.5 months, mPFS was 10.5 months (95 %CI, range 6, 13-
14, 87) for the whole group of patients including all subtypes. As expected, mPFS was 
different according the thyroid carcinoma subtypes (Figure 1), from 4.4 months (95 
%CI, range 2.30 - 6.57) in the anaplastic population to 13.3 months (95 %CI, range 
6.28 - 20.45) in patients with DTC and 10.5 months (95 %CI, range 4.49 - 16.51) in 
those with MTC. In terms of OS, the median for the whole group of patients was 23.6 
months, and when considering the different subtypes the figures were 5 months for the 
anaplastic tumor population, 23.6 months for the DTC population, whereas it was not 
reached for patients with MTC (Figure 2).  
Marker Correlation  
The correlation between the tumor marker decrease >50% and tumor response to 
sorafenib was analyzed. Thyroglobulin was used for DTC and calcitonin and/or CEA for 
MTC. Twenty-eight patients (82%) were evaluated for tumor marker response. In 16 
patients there was a decrease in any tumor marker >50% from baseline value, 8 of 
whom achieved PR. Of the 12 patients that did not show a decrease in tumor markers, 
only 1 patient presented PR. A statistically significant correlation was observed 
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between > 50% of any tumor marker decrease and the probability to achieve a tumor 
response by RECIST criteria (p<0.05. Chi-Square analysis) (Table 5). Analysis by 
tumor subtype and tumor marker type was did not show statistical significance due to 
low number of patients in each group. 
Toxicity 
The most common side effects (frequency of ≥ 5%) were hand-foot syndrome, 
diarrhea, rash, fatigue, anorexia, stomatitis, hypertension and abdominal pain. The 
majority of side effects were controlled with treatment delays or dose reductions. Table 
3 summarizes all the toxicity profile observed during the study period. Twelve patients 
(35%) required a dose reduction due to toxicity. There was one death from intracranial 
hemorrhage during the study, whose relationship with sorafenib cannot be ruled out.  
 
DISCUSION 
Until recently, medical management of advanced thyroid cancer refractory to standard 
treatments has been specially challenging. Classical DNA damaging drugs have 
demonstrated limited activity in this setting with no impact in survival. The knowledge of 
key mutational events in some genes including BRAF and RET that affect early stages 
of thyroid carcinogenesis has opened a new scene for targeted therapies. Sorafenib is 
the only available drug that target BRAF and RET and VEGF receptors also involved in 
the pathogenesis of thyroid cancers and offers a strong molecular rationale for the 
treatment of all thyroid cancer subtypes. 
In this retrospective study, the activity and safety of an unselected group of patients 
with all thyroid cancer subtypes treated with sorafenib in an off-label program has been 
reported. The study has been carried out following the currently Spanish legislation and 
in referral centers with experience in the management of targeted therapies in order to 
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obtain realistic data and minimize at maximum the typical biases of retrospective 
studies. Showed data is considered as of special interest since patients included in this 
analysis are real patients of routine clinical practice in comparison of usually selected 
patients included in clinical trials.  
The data obtained in this study are consistent with data obtained in previous studies 
with sorafenib and also with other tyrosine kinase inhibitors (TKIs) in DTC population in 
which the PR rate ranged from 6% to 49% (20% in this study), SD from 38% to 67% 
(50% in this study) and mPFS from 15 to 20 months (13.3 months in this study). 
However, certain discrepancies may be seen probably related to different inclusion 
criteria between studies, such as initial documented disease progression status (Table 
4). Currently, there is a deep discussion about the best criteria to evaluate antitumor 
activity of targeted therapies, and it seems that RECIST criteria do not properly 
evaluate all the real benefit of new targeted agents in solid tumors. We chose RECIST 
v 1.0 criteria instead of RECIST v 1.1 criteria to try to assess the maximum number of 
target lesions in the same organ as RECIST v 1.1 criteria reduces the number of target 
lesions per organ and this could jeopardize the best evaluation of a disease that 
usually metastasize to one or two different organs with measurable disease (lymph 
nodes and lung)14. 
Data of sorafenib in MTC is clearly limited compared with data in DTC. Other TKIs 
have demonstrated promising activity against MTC, such as XL-184, sunitinib or 
motesanib, and specially vandetanib that has recently obtained the Food and Drug 
Administration (FDA) approval for the treatment of advanced MTC after the positive 
results of a placebo-controlled phase III study that demonstrated significant benefit in 
mPFS (19.3 months for the placebo group versus median not reached for the group of 
patients treated with vandetanib). The few data available with sorafenib in MTC 
patients has showed limited activity with PR rates <10% but higher SD rates especially 
in subgroup analyses of patients with tumor progression before study entry15. The data 
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reported in this study support the efficacy of sorafenib in MTC population reaching 
similar data compared with other TKIs in this setting (Table 4). Although trials are not 
directly comparable it seems that different TKIs are able to obtain significant benefit in 
MTC patients, regardless the affinity against wild-type or mutant RET receptor, raising 
the important issue about carcinogenesis mutations and tumor addiction.  
In ATC patients, the number (n=3) renders it difficult to mainstream the data obtained 
from PR or SD. The results observed only generate the hypothesis of possible activity 
of TKIs in ATC. However, since TKIs may need some time to achieve active plasma 
concentration and reduction in tumor angiogenesis, these small molecules may be not 
as fast as desired, so their use in ATC should be considered carefully. 
The toxicity profile observed in this unselected cohort of patients was similar to that 
observed in previous studies and was managed mainly with both symptomatic 
measures and sorafenib dose delay or reduction (35% in this study). It is of special 
interest the safety profile observed in routine clinic thyroid cancer patients since usually 
toxicity data reported in selected patients included in prospective studies does not 
exactly match the reality. Although few patients presented grade 3-4 related toxicity, 
most patients presented some grade 1-2 side effects, which in some of them, 
previously asymptomatic, could represent a worsening in quality of life that can 
jeopardize the compliance to the treatment. Quality of life assessment is strongly 
suggested for future regulatory clinical trials. 
With regard to tumor markers and their role in the evaluation of clinical efficacy, a 
reduction in CEA/calcitonin and thyroglobulin higher than 50% was correlated with PR 
in this study. When data by tumor subtype and tumor marker type were analyzed the 
results were not significant due to the reduced number of patients. Data on this field 
are contradictory in phase II clinical trials and the results of this study only generate the 
hypothesis of possible predictive biomarkers for tumor response. These results should 
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be validated in prospective large phase III clinical trials and also provide information of 
the duration to achieve marker response (not available in this study) in order to 
recognize within few weeks, those patients who are very less likely/unlikely to get 
objective response and shorten drug exposure. 
 
CONCLUSIONS 
In summary, the results of this study show the efficacy and toxicity profile of sorafenib 
for the treatment of advanced and refractory thyroid cancer in an unselected 
population-based study that represents the scene of routine clinical practice. Similar 
efficacy data has been observed compared with other published studies with sorafenib 
in DTC patients. However, this study shows a cohort of patients with MTC with 
interesting clinical activity that warrants further development in this setting.  
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Table 1. Patient Characteristics   
Total nº of patients 34 
Gender M/F (Nº) 16/18 
Median age (range) 57,3 years (range 28,8-84,6) 
ECOG /PS N (%) 
                 0 5 (15) 
                 1 20 (59) 
                 2 9 (26) 
Tumor subtypes N (%) 
Papillary 7 (23) 
Follicular 9 (26) 
Medullary 15 (44) 
Anaplastic 3 (7) 
Previous therapies N (%) 
Surgery 33 (97) 
Radiotherapy 19 (56) 
Radioiodine therapy 13 (38) 
Chemotherapy 11 (32) 
Somatostatin analogs 7 (20) 
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Table 2. Tumor Response by subtypes 
 PR SD PD 
Papillary 14 % (1/7) 43 % (3/7)  43% (3/7) 
Follicular 22 % (2/9) 55 % (5/9) 11 % (1/9) 
DTC 19 % (3/16) 50 % (8/16) 25 % (4/16) 
Medullary 47 % (7/15) 40 % (6/15) 7 % (1/15) 
Anaplastic 33 % (1/3) 0% 66 % (2/3) 
 
Table 3. Main Side Effects.  
N=34 
 Grade 1 Grade 2 Grade 3 Grade 4 
Hand-Foot Syndrome 7 (20%) 6 (18%) 7 (20%) 1 (3%) 
Stomatitis 6(18%) 9 (26%) 1 (3%)  
Diarrheas 6 (18%) 10 (29%) 5(15%)  
Alopecia 3 (9%) 2 (6%) 4 (12%)  
Hypertension 4 (12%) 2 (12%)   
Abdominal Pain 5 (15%) 5 (15%) 1 (3%)  
Rash 8 (23%) 2 (6%) 2 (6%)  
Dry Mouth 1 (3%) 1(3%)   
Fatigue 8 (23%) 6 (18%) 5 (15%)  
Anorexia 1 (3%) 3 (9%) 3 (9%)  
Xerosis  9 (26%) 1 (3%) 1 (3%)  
Dysgeusia 1 (3%)    
Arthromyalgia 1    
Elevated transaminases   1 (3%) 1 (3%) 
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Table 4. Main studies in advanced thyroid cancer with targeted therapies. 
Authors Drug N Tumor 
Type 
Response 
Rate (%) 
Stable 
Disease 
(%) 
Median Progression-free 
Survival 
Kloos16 Sorafenib 41 DTC & 
ATC 
15 56 15 months 
Gupta-
Abramson17 
Sorafenib 30 DTC 23 34 20 months 
Hoftijzer18 Sorafenib 32 DTC 25 34 13.4 months 
Ahmed19 Sorafenib 26 DTC & 
MTC 
18* 82 NR 
Sherman20 Motesanib 93 DTC 14 67 9.2 months 
Cohen21 Axitinib 60 All 30 38 18.1 months 
Ravaud22 Sunitinib 17 All 30 38 NR 
Carr23 Sunitinib 33 DTC & 
MTC 
32 48 NR 
Bible24 Pazopanib 37 DTC 49 NR 11.7 months 
Leboulleux25 Vandetanib 145 DTC 8.3 56.9** 11 months 
De Souza26 Sunitinib 25 MTC 33 54 12 months 
Kurzrock27 XL-184 37 MTC 29 41 NR 
Wells28 Vandetanib/Placebo+ 331 MTC 45 NR 19.3 months vs  
Not reached 
Lam15 Sorafenib 21 MTC 6.3 87.5 17.9 months 
*3 months median follow-up; **Disease control rate; + Phase III study; DTC: differentiated thyroid cancer; ATC: 
anaplastic thyroid cancer; MTC: medullary thyroid cancer; NR: not reported. 
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Table 5. Correlation of tumor marker decrease > 50% and response  
 Decrease > 50% Total 
Yes No 
Partial Response Yes 8 1 9 
No 8 11 19 
Total 16 12 28 
P<0.05 Chi-Square 
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Figure 1. Median progression-free survival curves. Statistically significant 
differences were observed between DTC and anaplastic, and also between 
medullary and anaplastic. No differences were observed for DTC and MTC. 
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 Figure 2. Median overall survival curves. Statistically significant differences were 
observed between DTC and anaplastic, and also between MTC and anaplastic. 
No differences were observed between DTC and MTC. 25 
apdevila Castillón 
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a)  
b)  
Image 1:  a) On December 2007, baseline CT scan showed maximum diameters of 9 cm x 9 cm 
x 5 cm.  b) On January 2009 a partial response was confirmed with maximum diameters of 5.5 
cm x 5 cm x 4 cm.  
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